Document is current
Any future updates will be listed below
-
Authors
Grimm, Kai https://orcid.org/0000-0003-3561-3328
Sadeghi, Fatemeh https://orcid.org/0000-0002-9948-5866
Schön, Gerhard https://orcid.org/0000-0003-2556-6804
Okar, Abdullah
Gelderblom, Mathias https://orcid.org/0000-0002-4254-3439
Schulz, Robert https://orcid.org/0000-0003-0913-899X
Zittel, Simone https://orcid.org/0000-0002-3767-6376
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 25 September 2024
First Online: 7 October 2024
Declarations
:
: No author has any conflicts of interest that are related to the manuscript.
: Kai Grimm, Gerhard Schön and Abdullah Okar have no relevant financial or non-financial interests to disclose. Fatemeh Sadeghi received funding from the Werner Otto Foundation. Mathias Gelderblom is on the advisory board of Merz Pharmaceuticals and received honoraria from Merz Pharmaceuticals, AbbVie and Ipsen. Robert Schulz received funding from the German Research Foundation, Damp Stiftung and the Else Kröner-Fresenius-Stiftung. Simone Zittel is on the advisory board of Biomarin and received honoraria from Biomarin and Merz Pharmaceuticals. She received grant funding from the German Research Foundation, the European Commission, the Damp Foundation and the Arbeitskreis Botulinumtoxin.
: All participants completed safety questionnaires for MRI and provided written informed consent in accordance with the Declaration of Helsinki.
: The study was approved by the local ethics committee.
